Rebiotix’s Phase 3 Ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017

Data Analyses from Phase 2 (PUNCH CD) and Phase 2B (PUNCH CD2) Clinical Trials of RBX2660 Focus on Changes in Microbiome Diversity, Universal Donor Findings, and the Lack of Association with Patient Demographics on Treatment Success


Download this press release (161 KB).

ROSEVILLE, MN (May 04, 2017) — Rebiotix Inc., a clinical-stage microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that data analyses from the Phase 2 (PUNCH CD) and Phase 2B (PUNCH CD2) clinical trials of RBX2660 will be the subject of a podium presentation and two poster sessions during Digestive Disease Week (DDW) 2017 being held May 6-9, 2017 in Chicago. RBX2660 is a broad-spectrum microbiota suspension that is designed to rehabilitate the human microbiome by delivering live microbes into a patient’s intestinal tract to treat disease.

Lee Jones, president and CEO of Rebiotix, stated, “We are enthusiastic about the additional insight gleaned from the PUNCH CD and PUNCH CD2 trials of RBX2660 being presented at DDW. Overall, this is a very exciting time for Rebiotix. Based on the results of the Phase 2 program for RBX2660, including our recently announced positive top line data from the open-label Phase 2 study, we look forward to progressing RBX2660 into Phase 3 clinical development, solidifying our position as the most clinically advanced microbiome company in the industry.”

The schedule of Rebiotix-focused presentations at DDW is as follows:

Podium Presentation 

Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, a Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection: Results from PUNCH CD 2, a Randomized Double-Blind Placebo-Controlled Trial

Invetigators

Sahil Khanna, MBBS, MS, Gail Hecht, MD, Erik R. Dubberke, MD, MSPH, Robert Orenstein, DO, Christine H. Lee, MD, Dale N. Gerding, MD

Date & Time

Saturday, May 6th, 4:00 PM – 4:15 PM, CT

Session & Location

Session 2440; S102abc – McCormick Place

Poster Presentation

Lack of Association with Patient Demographics and Outcomes in PUNCH CD 2, a Randomized Controlled Trial of RBX2660, a Microbiota-Based Drug for Recurrent Clostridium difficile Infection

Investigators

Gail Hecht, Robert Orenstein, Erik R. Dubberke, Christine Lee, Sahil Khanna

Day & Time

Tuesday, May 9th; 12:00 PM – 2:00 PM, CT

Session & Location

Session 9130; South Hall – McCormick Place

Poster Presentation

Donors are Universal in the Fight Against Clostridium difficile: Results from Two Trials Investigating the Safety and Efficacy of RBX2660, a Microbiota-based Drug

Investigators

Arnab Ray, MD, Courtney Jones, BS, Bill Shannon, PhD, MBA , Sharina Carter, BSr

Day & Time

Tuesday, May 9th; 12:00 PM – 2:00 PM, CT

Session & Location

Session 9130; South Hall – McCormick Place


About Rebiotix Inc.

Rebiotix Inc. is a clinical-stage microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix is the most clinically advanced microbiome company in the industry, with its lead drug candidate, RBX2660, expected to enter Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff.) infection. Previously, RBX2660 was the subject of three Phase 2 trials in recurrent C. diff, including a Phase 2b randomized, double-blind, placebo-controlled trial (PUNCH™ CD2), with data indicating the drug was well-tolerated and demonstrated statistically significant treatment efficacy. RBX2660 has been granted Orphan Drug status, Fast Track status and Breakthrough Therapy Designation from the FDA for its potential to prevent recurrent C. diff. infection. Rebiotix’s development pipeline includes multiple formulations targeting several disease indications and is built around its pioneering Microbiota Restoration Therapy (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad spectrum of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.

Rebiotix Media Contact:

Jason Rando
Tiberend Strategic Advisors
212-375-2665
jrando@nulltiberend.com